Table of Contents
Select a link below to start reading online free!
Front Matter	i-xviii
Executive Summary and Recommendations	1-20	(skim)
1 Introduction and Background	21-45	(skim)
2 The Regulatory Framework for Protecting Humans in Research	46-65	(skim)
3 Scientific Justification for and Conduct of Intentional Human Dosing Studies	66-83	(skim)
4 A Risk-Benefit Framework for Assessing Intentional Human Dosing Studies	84-109	(skim)
5 Ethical Considerations in the Review of Intentional Human Dosing Studies	110-131	(skim)
6 Procedures for EPA Review of Intentional Human Dosing Studies	132-143	(skim)
7 EPA's Use of Data from Intentional Human Dosing Studies in Risk Assessment	144-158	(skim)
Appendix A: Values and Limitations of Animal Toxicity Data	159-167	(skim)
Appendix B: Pharmacokinetics and Metabolism of Pesticides	168-172	(skim)
Appendix C: Biographical Sketches of the Members and Staff of the Committee on the Use of Third Party Toxicity Research with Human Research Participants	173-184	(skim)
Appendix D: Biographical Sketches of the Members of the Science, Technology, and Law Panel	185-191	(skim)
Appendix E: Meeting Agendas	192-200	(skim)
Appendix F: Combined Registrants List for All Meetings	201-208	(skim)

Description

The EPA commissioned The National Academies to provide advice on the vexing question of whether and, if so, under what circumstances EPA should accept and consider intentional human dosing studies conducted by companies or other sources outside the agency (so-called third parties) to gather evidence relating to the risks of a chemical or the conditions under which exposure to it could be judged safe. This report recommends that such studies be conducted and used for regulatory purposes only if all of several strict conditions are met, including the following:

The study is necessary and scientifically valid, meaning that it addresses an important regulatory question that can t be answered with animal studies or nondosing human studies;

The societal benefits of the study outweigh any anticipated risks to participants. At no time, even when benefits beyond improved regulation exist, can a human dosing study be justified that is anticipated to cause lasting harm to study participants; and

All recognized ethical standards and procedures for protecting the interests of study participants are observed.

In addition, EPA should establish a Human Studies Review Board (HSRB) to evaluate all human dosing studies both at the beginning and upon completion of the experiments if they are carried out with the intent of affecting the agency's policy-making.

Authoring Organizations

• Policy and Global Affairs (PGA)
• More Titles from PGA

Search This Book

»Find more like this book

SIGN UP FOR...

New Title Emails
Read about the newest releases and receive special offers.